RxDoctor Payments Data

Douglas Katsev, MD

Ophthalmology · Santa Barbara, CANPI 1801906722

Payments from drug & device makers

$468,183in general payments, 2019–2025

Across 1,385 payments — averaging $338.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$125K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$98K
  • Kala Pharmaceuticals, Inc.$46K
  • Alcon$46K
  • Sun Pharmaceutical Industries Inc.$31K
  • Shire North American Group Inc$29K
  • plus $93K from 41 others

What the payments were for

  • Consulting fees$112,15624%
  • Speaking & faculty fees$237,38052%
  • Travel & lodging$62,23314%
  • Food & beverage$46,90710%
  • Education$110%
  • Gifts$1850%
  • Entertainment$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$468,183 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$1,001,304
Medicare patients
1,442
Services billed
8,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj24$787,751
MieboPerfluorohexyloctane/Pf146$118,202
XiidraLifitegrast61$52,162
RestasisCyclosporine24$28,363
ZyletTobramycin/Lotepred Etab46$15,998
Lotemax SmLoteprednol Etabonate40$10,977
TyrvayaVarenicline Tartrate11$8,337
LumiganBimatoprost13$7,539
EysuvisLoteprednol Etabonate14$7,091
Doxycycline Monohydrate187$4,981
Prednisolone Acetate138$4,891
BesivanceBesifloxacin Hcl21$4,857
Cyclosporine13$4,529
Loteprednol Etabonate26$3,994
Tobradex StTobramycin/Dexamethasone13$2,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$1,177$787,75124 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$124,947$170,364207 claims
AbbVieRestasis, Lumigan, Vuity$14,130$36,82749 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Lotemax Sm, Besivance, Loteprednol Etabonate$97,514$35,827133 claims
Oyster Point Pharma, Inc.Tyrvaya$969$8,33711 claims
Kala Pharmaceuticals, Inc.Eysuvis$46,015$7,09114 claims
Eyevance Pharmaceuticals LLCTobradex St$8,202$2,98113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →